Wang et al. 2020 (PRJNA612239)

Title	Chromatin state maintains human myeloid leukemia by regulating m6A demethylase ALKBH5 expression [Ribo-seq]
Organism
Number of Samples	4
Release Date	2020/03/11 00:00
Sequencing Types
Protocol Details

GWIPS-viz	Trips-Viz

Title
Authors	Wang J,Li Y,Wang P,Han G,Zhang T,Chang J,Yin R,Shan Y,Wen J,Xie X,Feng M,Wang Q,Hu J,Cheng Y,Zhang T,Li Y,Gao Z,Guo C,Wang J,Liang J,Cui M,Gao K,Chai J,Liu W,Cheng H,Li L,Zhou F,Liu L,Luo Y,Li S,Zhang H
Journal	Cell stem cell
Publication Date	2020 Jul 2
Abstract	N 6 -methyladenosine (m 6 A) is a commonly present modification of mammalian mRNAs and plays key roles in various cellular processes. m 6 A modifiers catalyze this reversible modification. However, the underlying mechanisms by which these m 6 A modifiers are regulated remain elusive. Here we show that expression of m 6 A demethylase ALKBH5 is regulated by chromatin state alteration during leukemogenesis of human acute myeloid leukemia (AML), and ALKBH5 is required for maintaining leukemia stem cell (LSC) function but is dispensable for normal hematopoiesis. Mechanistically, KDM4C regulates ALKBH5 expression via increasing chromatin accessibility of ALKBH5 locus, by reducing H3K9me3 levels and promoting recruitment of MYB and Pol II. Moreover, ALKBH5 affects mRNA stability of receptor tyrosine kinase AXL in an m 6 A-dependent way. Thus, our findings link chromatin state dynamics with expression regulation of m 6 A modifiers and uncover a selective and critical role of ALKBH5 in AML that might act as a therapeutic target of specific targeting LSCs. Copyright © 2020 Elsevier Inc. All rights reserved.
PMC
PMID	32402251
DOI

ⓘ For more Information on the columns shown here see: About